Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEAT NMO: Belimumab in NMOSD
NCT05154734Phase 2Completed
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Dec 2021
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of belimumab in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Tianjin Medical University General Hospital. Primary endpoint: Number of Attacks at 1 year. Started Dec 2021; status: completed.
02
Drugs
belimumab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT05154734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05154734.